Symprove Ltd and the Advanced Wellbeing Research Centre (AWRC; Sheffield Hallam University) are looking for people with MS to take part in their 12-week trial to find out whether changes to the gut microbiome have potential benefits to people living with MS.
Researchers will look at the feasibility, acceptability, and potential benefits on symptoms and quality of life of taking a daily probiotic (Symprove) over a 12-week period for people with MS.
What is Symprove?
Symprove is a water-based food supplement. It contains four strains of live and active bacteria. These are delivered to the gut to support the microbiome.
When does the study take place?
The study will start in early 2023, it will take place over 12 weeks and is fully remote.
What will participants be asked to do?
You will be asked to take a probiotic daily for 12-weeks. To determine the feasibility of the outcome measures and explore potential benefits, Symprove will ask you to carry out an assessment at the start and end of the 12-weeks. This will include a questionnaire about some of your current symptoms and quality of life and taking a small poo sample for analysis of your gut-microbiome. They will also ask you to complete a short acceptability questionnaire and participate in a small focus group at the end of the 12-weeks.
Who can join?
They are looking for people with a diagnosis of Multiple Sclerosis based in the UK, who do not have a rapidly progressing disease or any reason why they should not take a probiotic.